Investor Relations
Mar 23, 2018
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes MORE >>
Mar 16, 2018
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology MORE >>
Mar 01, 2018
OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results MORE >>
Feb 26, 2018
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018 MORE >>

Press Releases

All Releases
OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes
Mar 23, 2018
MIAMI , March 23, 2018 (GLOBE NEWSWIRE) -- OPKO Health , Inc.  (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and
OPKO Health Announces Landmark Study Showing 4Kscore® Test is Strong Predictor of Prostate Cancer Mortality Published in European Urology
Mar 16, 2018
Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI , March 16, 2018 (GLOBE NEWSWIRE) --   OPKO Health, Inc. (NASDAQ:OPK) today announced that data from a landmark study of the 4Kscore® test
OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results
Mar 01, 2018
Conference Call begins today at 4:30 p.m. Eastern Time
OPKO Health to Announce Fourth Quarter and Year End 2017 Financial Results on March 1, 2018
Feb 26, 2018
MIAMI , Feb. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), plans to announce its operating and financial results for the three and twelve months ended December 31, 2017 , after the close of the U.S. financial markets on Thursday, March 1, 2018 .
OPKO Health Announces Leadership Changes at BioReference Laboratories
Jan 26, 2018
MIAMI , Jan. 26, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that Gregory Henderson , M.D., Ph.D., has resigned from his position as President of BioReference Laboratories , an OPKO Health company and the third largest commercial laboratory in the United States , effective
OPKO'S GeneDx Announces Research Collaboration with Radboud University Medical Center
Jan 12, 2018
Aimed at identifying novel genes and pathways to help manage human genetic diseases
OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Nov 27, 2017
Enlarged Prostate Affects Approximately 50 Million Men in the U.S.
OPKO Health Reports 2017 Third Quarter Highlights and Financial Results
Nov 08, 2017
RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016 4Kscore TV ads in the Northeast to begin November 21 Submitted a Premarket Approval (PMA) application with FDA for Claros point-of-care (POC) prostate
OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros® 1 Platform
Nov 07, 2017
Addresses a $625 million U.S. market opportunity
OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017
Nov 03, 2017
MIAMI , Nov. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2017 , after the close of the U.S. financial markets on Wednesday, November 8, 2017 .
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy
Oct 26, 2017
OPKO to receive tiered double-digit royalties on product sales
OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan
Oct 12, 2017
OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales
OPKO's BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care
Sep 19, 2017
Providing clinicians with advanced tools to guide quality, value-based care; affiliation to be showcased during the NAACOS Fall 2017 Conference in Washington, DC from Oct. 4-6
OPKO's GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings
Sep 12, 2017
Demonstrates Commitment to Scientific and Clinical Advancement with More Than 35 Poster and Podium Presentations
OPKO Health to Present at Upcoming September Conferences
Aug 31, 2017
MIAMI , Aug. 31, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) ("OPKO" or "the Company"), announces that management will present a corporate update, which will include an update on its hGH development program, at the following upcoming September 2017 investor conferences: 2017 Wells Fargo
OPKO Health Reports Second Quarter 2017 Business and Financial Results
Aug 08, 2017
Conference call begins at 4:30 p.m. Eastern time today
OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017
Aug 03, 2017
MIAMI , Aug. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months and six months ended June 30, 2017 , after the close of the U.S.
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 22, 2017
Updated Guideline Highlights the Limitations of Current Treatments for Secondary Hyperparathyroidism in Patients with Stage 3 or 4 Chronic Kidney Disease and Acknowledges Rayaldee as a Novel Vitamin D Prohormone
OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults
Jun 15, 2017
MIAMI , June 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces an update to the topline data analysis of the Phase 3, double-blind, placebo-controlled study of its investigational long-acting human growth hormone product (hGH-CTP) in adults with growth hormone deficiency (GHD).
OPKO'S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing
Jun 07, 2017
OPKO Helps Expand UC Health's leadership at the forefront of precision medicine
Displaying 1 - 20 of 348